Novocure's long-term data results of its Phase 3 EF-14 trial involving Optune combined with temozolomide are consistent with the results from the interim analysis of the data. Read More »

Celgene Corp. has purchased Triphase Accelerator Corp.'s assets regarding its proteasome inhibitor, marizomib, which is being developed for the treatment of glioblastoma and relapsed and/or refractory multiple myeloma. Read More »

Merck KGaA's businesses in Massachusetts have been ranked among the “Top Places to Work” by The Boston Globe. Read More »

Bayer has formed a Phase 3 clinical trial that will assess the safety and effectiveness of Nifurtimox, a formulation designed to treat children of all ages that have been diagnosed with Chagas disease. Read More »

CSL Behring's Phase 2b clinical trial involving AEGIS-I has turned in positive results. Read More »

Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »

Akcea Therapeutics' Phase 1/2 trial involving IONIS-ANGPTL3-LRx has turned in positive results. Read More »

Alnylam Pharmaceuticals published results from its Phase 1 clinical trial involving inclisiran in The New England Journal of Medicine. Read More »

Bristol-Myers Squibb and Innate Pharma have released the interim effectiveness analysis of its Phase 1/2 trial involving the lirilumab and Opdivo combination. Read More »

Crescendo Biosciences gave four poster presentations showcasing Vectra DA at the American College of Rheumatology meeting in Washington D.C. this week. Read More »

The American Cancer Society has partnered with the CVS Health Foundation to present grants to 20 institutions across the United States for their Tobacco-Free Generation Campus Initiative. Read More »

Merck has received the R&D 100 Award from R&D magazine. Read More »

Janssen-Cilag International NV's STELARA has been approved by the European Commission to treat adult patients who have moderate-to-severe Crohn’s disease and did not respond well to or are immune to conventional therapy or a tumor necrosis factor alpha antagonist. Read More »

Biothera Pharmaceuticals recently presented new Phase 2 Imprime PGG preclinical data that will corroborate the drug’s ability to produce coordinated innate and adaptive immune responses that could increase the effectiveness of other checkpoint inhibitor therapies. Read More »

Imprimis Pharmaceuticals has reached a purchase and supply agreement with the specialty pharmacy division of one of the country’s biggest pharmacy benefits managers Read More »

Amgen plans to partner with Janssen Biotech to further assess the drug combination of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen. Read More »

Vemlidy, Gilead Sciences’s treatment for chronic hepatitis B virus with compensated liver disease, has been approved by the U,S. Food and Drug Administration. Read More »

The Prostate Cancer Foundation has revealed its new corporate identity, which includes the tagline “Curing Together.” Read More »

McKesson Specialty Health hosted its two-day 2016 Onmark Fall Leadership Summit in Orlando, Florida, featuring the possible transformation that community oncology practices are having to make so they can survive in the ever-evolving world of care based on value and payment reform. Read More »

Prime Therapeutics has released a guide on how to enroll in health insurance to avoid tax penalties. Read More »